Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Diagnostics 

EMA launches consultation on companion diagnostics and personalised medicine

The European Medicines Agency (EMA) has launched a concept paper for public consultation on the development and lifecycle of personalised medicines and companion diagnostics (CDx) — devices used to help assess the most likely response to a particular treatment and determine the correct dose.

Personalised medicines are individualised treatments targeted to patients on the basis of their characteristics and unique genetic makeup.

The choice of a personalised medicine relies on the use of CDx, defined in the paper as a diagnostic medical device, often used in vitro, which enables healthcare professionals to identify patients who are most likely to benefit from the corresponding medicinal product and those most likely to be at increased risk of a serious adverse reaction.

CDx can also be used to monitor response to treatment, with the purpose of adjusting treatment to improve safety or effectiveness.

The aim of the paper is to help optimise the co-development of medicinal products and CDx, which are currently developed independently, coming together only in the end. This can lead to gaps in evidence and validations.

Among its recommendations the paper therefore calls for a close-knit development group linking the medicinal product and CDx, and use of clinical trials to generate evidence to support validation of the diagnostic.

If developed into a guideline, the paper will replace the reflection paper on co-development of pharmacogenomics biomarkers and analysis in the context of drug development.

According to the EMA, it is the first step in the preparation of a guideline that will address the challenges associated with the development of personalised medicines with CDx.

The consultation closes on 15 November 2017 and it is anticipated that a draft guideline will be available 9–12 months after the end of the public consultation of the concept paper, which will then be released for 6 months external consultation.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20203318

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • pill box personalised medicine

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.